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Objective: The purpose of this study was to investigate whether prostaglandin E2 (PGE2) induces Signal transducer and activator of
transcription 3 (Stat3) activation in neonatal rat ventricular cardiomyocytes and if so to determine the possible role of this activation in PGE2-
induced hypertrophic responses.
Methods: Stat3 activation and its nuclear phosphorylation were determined by electrophoretic mobility shift assay (EMSA) and by Western
blots, respectively. Protein synthesis was assessed by [3H]-leucine incorporation into total protein and cell surface was quantified by
microscopic analysis.
Results:We found that PGE2 induces a concentration- (1–100 nM) and time-dependent increase in Stat3 activation, reaching maximal values
after 90 min of stimulation. Experiments with agonists and antagonists of the PGE2 receptor subtypes EP1–EP4 indicate that PGE2 activates
Stat3 mainly through the EP4 receptor. We further observed that the extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor U0126
abolishes PGE2-induced Stat3 activation whereas the p38 MAP kinase blocker SB203580 has no effect. Nuclear Stat3 phosphorylation
induced by PGE2 is also suppressed by the translation and transcription inhibitors, cycloheximide and actinomycin D, respectively.
Transfecting ventricular cardiomyocytes with a small interfering RNA (siRNA) targeting rat Stat3, we obtained an approximately 70%
reduction in Stat3 expression, 24 and 48 h after electroporation. In these Stat3-silenced cells, the PGE2-induced increase in protein synthesis
and cell surface is strongly inhibited.
Conclusion: In ventricular cardiomyocytes, PGE2 induces the activation of Stat3 which plays an essential role in PGE2-induced increase
in cell size and protein synthesis. The activation of Stat3 occurs mainly through EP4 and involves ERK1/2 as well as newly synthesized
protein(s).
© 2006 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.Keywords: Hypertrophy; Prostaglandins; Signal transductionThis article is referred to in the Editorial by Schaub and
Hefti (pages 3–5) in this issue.
1. Introduction
Prostaglandin E2 (PGE2) is involved in multiple physi-
ological and pathological processes such as vasodilation,
proliferation and inflammation. In the heart, PGE2 has been
shown to be secreted under stress conditions including myo-⁎ Corresponding author. Tel.: +41 22 3729322; fax: +41 22 3729330.
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doi:10.1016/j.cardiores.2006.09.016cardial infarction [1]. We have previously shown that PGE2
is released in ventricular cardiomyocytes following stimu-
lation with aldosterone [2] which has been reported to induce
ventricular hypertrophy in rats [3]. Similarly, increased car-
diac PGE2 production was reported in an animal model of
left ventricular hypertrophy [4]. Recently, PGE2 was found
to induce hypertrophic responses such as an increase in cell
surface and protein synthesis as well as an activation of ANP
and BNP promotors in ventricular cardiomyocytes through
the PGE2 receptor subtype EP4 [5,6].
The development of cardiac hypertrophy is a complex
process involving a variety of signaling pathways. A numberd by Elsevier B.V. All rights reserved.
Fig. 1. PGE2 induces a time- and concentration-dependent increase in
nuclear Stat3 phosphorylation in rat ventricular cardiomyocytes. Cells were
treated or not with PGE2 (100 nM) during different time periods (30–
120 min, A) or for 90 min with increasing concentrations of PGE2 (1–
100 nM, B). Thereafter, Stat3 phosphorylation (Stat3-P) was analyzed in
nuclear extracts byWestern blots. A representative blot is shown at the top of
(A) and (B). Equal gel loading was assessed using an anti-TFIIEα antibody.
Specific bands corresponding to phosphorylated Stat3 were quantified by
densitometry and expressed as percentage of the corresponding control.
⁎=pb0.05 compared with control values (n=4).
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of transcription 3 (Stat3) plays a major role in the development
of cardiac hypertrophy [7–9]. Indeed, cardiac specific over-
expression of the Stat3 gene in transgenic mice results in
myocardial hypertrophy with an increased expression of ANP
andβ-MHC [7]. Stat3 is activated under stress conditions such
as pressure overload and acute myocardial infarction as well as
by the hypertrophic hormone angiotensin II [10–13]. More-
over, Stat3 promotes cardiomyocyte survival and hypertrophy
in response to various pathophysiological stimuli [14–16].
As reported in several studies, the extracellular signal-
regulated kinase 1/2 (ERK1/2) pathway is another signaling
cascade playing an important role in the development of
cardiac hypertrophy. Indeed, multiple in vivo and in vitro
studies, using pharmacological and genetic approaches,
showed that the MEK1/2–ERK1/2 signaling cascade reg-
ulates important aspects of the hypertrophic response in
cardiomyocytes [17–19].
At the present time there is no information concerning the
effects of PGE2 on Stat3 in cardiac cells. In this study we
investigated the mechanism of action of PGE2-induced Stat3
activation involving ERK1/2 as well as the role of Stat3 in
PGE2-stimulated hypertrophic responses in neonatal rat ven-
tricular cardiomyocytes.
2. Material and methods
2.1. Cell culture
This investigation conforms with the Guide for the Care
and Use of Laboratory Animals published by the USNational
Institutes of Health (NIH Publication No. 85-23, revised
1966). Neonatal cardiac cells were isolated from 1 to 2-day-
old Wistar rats ventricles by digestion with trypsin-EDTA
and type 2 collagenase as previously described [20]. Briefly,
once the sequential digestions were terminated, the cells were
pooled in Dulbecco's modified Eagle's medium (DMEM,
Invitrogen, Groningen, the Netherlands) supplemented with
10% fetal calf serum (FCS, BiochromAG, Berlin, Germany),
penicillin (100 units/ml) and streptomycin (10 μg/ml) and
seeded in 150 cm2 flasks to allow selective adhesion of
cardiac fibroblasts [21]. Thereafter, cardiomyocytes were
decanted from the plates and seeded in petri dishes (60 or
90 mm, Costar, Cambridge, MA). The majority of cul-
tured cardiomyocytes began to contract spontaneously within
24–48 h of plating (30–50 beats/min). For all experiments
described herein, cells were used in the third day of culture,
after 16–20 h in DMEM medium depleted in FCS.
2.2. Western blotting
Cardiomyocytes were starved of serum overnight and
subjected to treatment as indicated in the figure legends.
After stimulation in serum-free DMEM, cells were washed
with ice-cold PBS and lysed with 50 μl of the following
buffer: Tris-HCl (50 mM, pH 7.4), NaCl (150 mM), glycerol(10%), EDTA (2 mM), EGTA (2 mM), Triton X-100 (1%),
β-glycerophosphate (40 mM), NaF (50 mM) containing a
cocktail of protease inhibitors (Roche, Mannheim, Ger-
many). In order to inhibit serine/threonine and tyrosine
dephosphorylation, we inhibited serine/threonine and tyro-
sine phosphatases by okadaic acid (100 nM) and sodium
orthovanadate (0.2 mM) respectively.
Nuclear or total cell proteins (10–30 μg) were separated
by SDS-PAGE on an 8 or 12% acrylamide gel and blot-
ted onto nitrocellulose membrane. Afterwards, membranes
were incubated overnight at 4 °C with specific polyclonal
antibodies. The blots were then washed and incubated for 1 h
with a horseradish peroxidase-labeled anti-rabbit antibody
(Covalab, Oullins, France). Specific bands were visu-
alized with a chemiluminescence kit (Amersham, Zürich,
Fig. 2. PGE2 induces an increase in Stat3 phosphorylation essentially through EP4. (A) Cells were incubated for 30 min with the specific EP4 antagonists,
GW627368X (5 μM) or AH23848B (50 μM) prior to stimulation with PGE2 (100 nM, 90 min). (B) Cells were treated for 30 min with AH6809 (EP1/EP2
antagonist, 10 μM) and SC19220 (EP1 antagonist, 10 μM) prior to stimulation with PGE2 (100 nM, 90 min). (C) Cardiomyocytes were stimulated with the EP1/
EP3 agonist sulprostone (100 nM and 1 μM) or PGE2 (100 nM) for 90 min. Stat3 phosphorylation (Stat3-P) was analyzed in nuclear extracts byWestern blotting.
Representative Western blots are shown in (A–C). Equal gel loading was assessed using an anti-TFIIEα antibody. Specific bands corresponding to
phosphorylated Stat3 were quantified by densitometry and expressed as percentage of the corresponding control. ⁎=pb0.05 compared with control values,
†=pb0.05 vs. PGE2 (n=4).
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total MEK1/2, ERK1/2 or the alpha subunit of the general
transcription factor TFIIE (TFIIEα). Total MEK1/2 and
ERK1/2 were used as controls for equal loading in cellular
extracts, whereas TFIIEα was used as control for equal
loading in nuclear extracts. Specific antibodies directed
against phosphorylated Stat3, MEK1/2, ERK1/2 and total
MEK1/2 were obtained from Cell Signaling Technology
(Denvers, MA), while total anti-Stat3 antibody was from
Upstate Biotechnology (Lake Placid, NY). Total ERK1/2,
Stat1 and TFIIEα were detected by specific antibodies from
Santa Cruz Biotechnology (Santa Cruz, CA).
2.3. Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared according to the proce-
dure of Schreiber et al. [22]. For EMSA, oligonucleotides
corresponding to the sis-inducible element (SIE) sequence
localized in the promoter region of the c-fos gene, were
annealed and radiolabeled with [γ-32P]dATP. Nuclear proteins
(10–20 μg) were incubated with 80’000 cpm of labeled
double-strandedDNA, 1μg of poly[d(IC)], 1μg salmon sperm
DNA and 1 μg BSA in EMSA binding buffer (20 mM HepespH 7.9, 5 mM MgCl2, 0.5 mM EDTA, 50 mM KCl, 1 mM
dithiothreitol and 6.25% glycerol) in a final volume of 25 μl.
The reaction mixture was run on a 5% polyacrylamide gel at
4 °C. Gels were dried, exposed to autoradiography films and
stored at–80 °C before development. In order to specify Stat3–
SIE DNA binding, 0.8 μg of a polyclonal anti-Stat3 antibody
(from Upstate Biotechnology or from Santa Cruz Biotechnol-
ogy) or anti-Stat1 antibody (from Santa Cruz Biotechnology)
were added to the reaction mixture containing the labeled
probe. To confirm the specificity of the labeled SIE DNA
probe, competition assay was performed using unlabeled SIE
DNA sequence.
2.4. siRNA transfection
Stat3 was silenced by using a small interfering RNA
(siRNA) targeting rat Stat3 with the following sequence: 5′-
GGCUGAUCAUUUAUAUAAA-3′. This siRNA which
was provided by Qiagen AG (Hombrechtikon, Switzerland)
was annealed according to manufacturer's instructions and
then stored at −20 °C. Cardiomyocytes were transfected with
siRNA in Nucleofector device (Nucleofector TM Amaxa
GmBH, Cologne, Germany) by using the Nucleofector rat
Fig. 3. PGE2 induces a time-dependent increase in MEK1/2 and ERK1/2
phosphorylation. Cells were treated or notwith PGE2 (100nM) during different
time periods (2–30min). Thereafter, phosphorylation ofMEK1/2 (MEK1/2-P)
and ERK1/2 (ERK1/2-P) was analyzed in cellular extracts byWestern blots. A
representative blot is shown at the top of (A) and (B). Equal gel loading was
assessed using an antibody against total MEK1/2 or ERK1/2. Specific bands
corresponding to phosphorylated forms of MEK1/2 (A) and ERK1/2 (B) were
quantified by densitometry and expressed as percentage of the corresponding
control. ⁎=pb0.05 compared with control values (n=4–7).
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4×106 cardiomyocytes suspended in 100 μl of Nucleofector
rat cardiomyocyte solution. Cells were subjected to nucleo-
fection using the cardiomyocyte specific program. For
control, cells were transfected with 3 μg of non-silencing
siRNA (5′-UUCUCCGAACGUGUCACGU-3′) which is
ineffective in rat cells since it has no mammalian target.
Transfected cells were immediately diluted in complete pre-
warmed DMEM medium and seeded in 24-well plates or on
fibronectin-gelatin-coated glass slides.
2.5. Microscopic analysis
After electroporation, cardiomyocytes were plated on
fibronectin-gelatin-coated 22-mm glass slides. Cells were
treated for 48 h with PGE2 (1 μM) or its vehicle, 0.1%
ethanol (control). For microscopic analysis of living neonatal
cardiomyocytes, cells were incubated in Hepes buffer (Hepes
10 mM, KCl 5 mM, NaHCO3 5 mM, glucose 5 mM, CaCl2
1.25 mM, MgCl2 1.2 mM, NaH2PO4 1.2 mM, NaCl
100 mM, sucrose to 290 milliosmol/kg H2O, pH=7.3). To
assure objectivity, all cardiomyocytes present in a micro-
scopic field (n∼50) were analyzed. Cell surface quantifica-
tion was performed using the photoshop 7.0 program.
2.6. [3H]-leucine incorporation
48 h after electroporation, cardiomyocytes were incubat-
ed with PGE2 (1 μM) or its vehicle, 0.1% ethanol (control)
and co-incubated with 5 μCi/ml of [3H]-leucine (Moravek
Biochemicals, Brea, CA) in FCS- and leucine-free DMEM.
After 12 h of stimulation, cardiomyocytes were washed
twice with PBS, treated with 10% TCA and left on ice for
30 min to precipitate proteins. The precipitated proteins were
washed with ice-cold ethanol 95% and then dissolved in
NaOH (0.2 N). [3H] incorporation was measured by scintil-
lation counting.
2.7. Chemicals
PGE2 and cycloheximide were purchased from Sigma–
Aldrich GmbH (Buchs, Switzerland). SB203580, U0126,
genistein and actinomycin D were from Calbiochem
(Dietikon, Switzerland), Biomol Research Laboratories
(Plymouth Meeting, PA), Alexis biochemicals (Lausen,
Switzerland) and Applichem GmbH (Darmstadt, Germany),
respectively. Sulprostone (EP1/EP3 agonist), SC19220 (EP1
antagonist) andAH6809 (EP1/EP2 antagonist) were obtained
from Cayman (Ann Arbor, MI) and AH23848B and
GW627368X (EP4 antagonists) were generously offered by
GlaxoSmithKline (Brentford Middlesex, United Kingdom).
2.8. Statistical analysis
All values are expressed as mean±SEM. Differences
between groups were determined using either two-tailedunpaired Student's t-tests or two-way ANOVA, followed by
Bonferroni's post-hoc test. Pb0.05 was accepted as statis-
tically significant.
3. Results
3.1. PGE2 induces nuclear Stat3 phosphorylation via EP4
The activation of Stat3 by PGE2 was first investigated by
measuring Stat3 phosphorylation in the nuclear extracts of
ventricular cardiomyocytes by Western blot. Since phos-
phorylation of Stat on tyrosine residues is necessary for its
activation, we tested the effect of PGE2 on Stat3 phosphor-
ylation by using an antibody recognizing the tyrosine 705
phosphorylated form of Stat3. As shown in Fig. 1A, PGE2
induces Stat3 phosphorylation on tyrosine 705 (Y705) in a
time-dependent manner, reaching a maximum value after
90 min of stimulation. This phosphorylation is also
Fig. 4. Stat3 activation is abolished by U0126 and genistein but not by SB203580. Cells were incubated for 30 min with U0126 (10 μM) or SB203580 (SB, 10 μM)
the inhibitors of ERK1/2 and p38 MAPK, respectively, or for 1 h with the tyrosine kinase inhibitor genistein (GEN, 100 μg/ml), prior to stimulation with PGE2
(100 nM, 90 min). (A) Stat3 phosphorylation (Stat3-P) was analyzed in nuclear extracts by Western blotting. A representative blot is shown at the top. Equal gel
loading was assessed using an anti-TFIIEα antibody and specific bands corresponding to phosphorylated Stat3 were quantified by densitometry and expressed as
percentage of the corresponding control. ⁎=pb0.05 compared with control values, †=pb0.05 vs. PGE2 (n=4–5). (B) The DNA-binding of Stat3 was analyzed in
nuclear extracts by EMSA using labeled SIE DNA. To determine Stat3 specific DNA-binding, 0.8 μg of two polyclonal antibodies against Stat3, from Upstate
Biotechnology (U) and from Santa Cruz Biotechnology (SC), as well 0.8 μg of an antibody against Stat1 were used. To confirm the specificity of the labeled DNA
probe, competition assaywas performed using a 100-fold excess of unlabeled SIEDNA (cold probe). The figure shows a representative example from 3 experiments.
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after 90 min of stimulation with 10 nM of PGE2 (Fig. 1B).
In order to determine which subtypes of the PGE2 re-
ceptor are involved in this response we used several agonists
and antagonists of the PGE2 receptor subtypes EP1–EP4. We
found that incubation of cardiomyocytes with the specific
inhibitors of EP4, GW627368X and AH23848B [23,24],
abolishes the PGE2-induced phosphorylation of nuclear
Stat3 (Fig. 2A). By contrast, treatment with AH6809 or
SC19220, the EP1/EP2 antagonist and EP1 antagonist,
respectively [25], had no effect on Stat3 phosphorylation
(Fig. 2B). A weak but significant effect on Stat3 phosphor-
ylation was observed after 90 min of stimulation with 1 μM
sulprostone, the EP1/EP3 agonist [25] (Fig. 2C). Thus, our
results indicate that PGE2 induces nuclear Stat3 phosphor-
ylation mainly via EP4, although a possible involvement of
EP3 cannot be excluded.
3.2. ERK1/2, but neither p38 MAPK nor cAMP, plays a role
in Stat3 activation induced by PGE2
Since ERK1/2 and p38 MAPK have been shown to act
as modulators of Stat3 activation in various cell systems[26–28], we studied their role in the activation of Stat3
induced by PGE2 in neonatal ventricular cardiomyocytes. To
this purpose we first studied the effect of PGE2 on the
phosphorylation of MEK1/2 (Fig. 3A), ERK1/2 (Fig. 3B)
and p38 MAPK. As shown in Fig. 3, we found that PGE2
induces a rapid and transient phosphorylation of MEK1/2
and ERK1/2 with significant responses observed after 2–
5 min. By contrast, PGE2 did not affect the phosphorylation
level of p38 MAPK (data not shown).
To further investigate the involvement of p38MAPKand the
ERK1/2 cascade in PGE2-induced Stat3 activation, we per-
formed experiments using their respective inhibitors, SB203580
and U0126. SB203580 exerts its inhibitory effect by binding to
the ATP site of p38 MAPK [29] while U0126 is reported to
block activation of ERK1/2 by suppressing the activation of
MEK1 [30,31]. Nuclear extractswere prepared after stimulation
of cardiomyocytes with PGE2 in the presence or absence of
U0126 or SB203580. The phosphorylation level of Stat3
(Y705)was assessed byWestern blotting (Fig. 4A) and the Stat3
DNA-binding by EMSA using the specific SIE sequence
localized in the promoter region of the c-fos gene (Fig. 4B).
As shown in Fig. 4A, 90 min of incubation with 100 nM
PGE2 increased the phosphorylation level of Stat3. Exposure
Fig. 5. Stat3 phosphorylation is abolished by cycloheximide and
actinomycin D. Cells were incubated for 15 min, with the translation
inhibitor cycloheximide (CHX, 10 μg/ml) or the transcription inhibitor
actinomycin D (Actino D, 2.5 μg/ml) prior to stimulation with PGE2
(100 nM, 90 min) and Stat3 phosphorylation (Stat3-P) was analyzed in
nuclear extracts by Western blotting. A representative blot is shown at the
top. Equal gel loading was assessed using an anti-TFIIEα antibody. Specific
bands corresponding to phosphorylated Stat3 were quantified by densitom-
etry and expressed as percentage of the corresponding control. ⁎=pb0.05
compared with control values, †=pb0.05 vs. PGE2 (n=3).
Fig. 6. Stat3 expression is strongly reduced by siRNA targeting Stat3.
Cardiomyocytes were electroporated with specific siRNA targeting Stat3 (si)
or non-silencing siRNA (control, ctl) for different periods of time, and Stat3
expression in cellular extracts (15 μg) was analyzed by Western blotting. A
representative blot is shown at the top. Equal gel loading and specificity
were assessed using an anti-Stat1 antibody. Specific bands corresponding to
Stat3 were quantified by densitometry and expressed as percentage of the
corresponding control. ⁎=pb0.05 compared with control values (n=3).
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2 pathway, abolished PGE2-induced Stat3 phosphorylation,
whereas inhibiting p38 MAPK with SB203580 (10 μM), had
no significant effect. As expected, the tyrosine kinase
inhibitor, genistein, abolished Stat3 tyrosine phosphorylation
induced by PGE2 (Fig. 4A).
Fig. 4B illustrates that 90min of stimulationwith PGE2 also
enhanced the SIE DNA-binding of Stat3. As for Stat3
phosphorylation, PGE2-induced Stat3 DNA-binding was
completely suppressed by U0126 and genistein while it was
only slightly affected by SB203580. In order to verify the
specificity of the Stat3 DNA-binding, we incubated nuclear
extracts from PGE2-stimulated cardiomyocytes and labeled
SIEDNA in the presence of anti-Stat3 or anti-Stat1 antibodies.
In the case of anti-Stat3, we used polyclonal antibodies from
two different sources, Upstate Biotechnology (U) and Santa
Cruz Biotechnology (SC). As shown in Fig. 4B, the specificity
of the Stat3/SIE DNA complex is demonstrated by the
disappearance of this complex in the presence of anti-Stat3 (U)
as well as by its shift to a higher position (supershift) in the
presence of anti-Stat3 (SC). By contrast, the anti-Stat1
antibody had no effect, confirming specific Stat3 binding
upon PGE2 stimulation. During competition assay with a 100-
fold excess of unlabeled SIE DNA (cold probe), the band
which corresponds to the binding of Stat3 to the SIE sequence
disappeared, confirming the specificity of SIE DNA binding.Since EP4 receptor was initially characterized as coupling
to the G-protein stimulating adenylate cyclase and increasing
cAMP [32], we investigated the potential role of cAMP-
dependent protein kinase A in PGE2-induced Stat3 phos-
phorylation. Incubation of cardiomyocytes with the cell-
permeant, cAMP competitive inhibitors of protein kinase A,
Rp-cAMPS (10 μM) and Rp-8-CPT-cAMPS (10 μM),
30 min prior to the stimulation with PGE2 for 90 min had
no effect on Stat3 phosphorylation induced by this prosta-
glandin. Consistent with this observation, the cAMP-raising
agent, forskolin (0.5 and 1 μM) did not increase Stat3
phosphorylation after 90min of stimulation (data not shown).
Having observed that Stat3 activation by PGE2 is delayed,
mainly occurring after 60 min of stimulation, we hypothesized
that newly synthesized proteins are necessary for this response.
Therefore, we blocked translation and transcription with cy-
cloheximide and actinomycin D, respectively. As illustrated in
Fig. 5, both inhibitors abolished nuclear Stat3 phosphorylation
induced by PGE2 without affecting Stat3 expression in cellular
extracts (data not shown). Our results indicate a role of ERK1/
2 but not of p38 MAPK in the activation of Stat3 induced by
PGE2. Moreover, it appears that newly synthesized protein(s)
are necessary for this response.
3.3. Stat3 plays a role in PGE2-induced hypertrophy
PGE2 was shown to increase protein synthesis and cell
surface in cardiomyocytes [5]. In order to evaluate whether
Fig. 7. siRNA targeting Stat3 blocks PGE2-induced increase in cell size and
protein synthesis. 40 h after electroporation, cardiomyocytes were treated or
not with PGE2 (1 μM). [
3H]-leucine incorporation into total protein was
measured after 12 h of incubation with PGE2 (A). Microscopic analysis was
performed after 48 h of exposure to PGE2 and cell surface (300–360 cells/
condition) was determined (B). ⁎=pb0.05 compared with control values,
†=pb0.05 vs. PGE2 (n=3–4).
Fig. 8. Proposed model of PGE2-induced Stat3 activation and hypertrophic
responses in the neonatal ventricular cardiomyocyte. PGE2 activates the EP4
receptor subtype which induces activation of the MEK1/2–ERK1/2
signaling cascade leading to the phosphorylation of Stat3 which also
needs newly synthesized protein(s). After its phosphorylation, Stat3
dimerizes and translocates to the nucleus where it promotes the transcription
of target genes leading to an increase in protein synthesis and cell size.
Abbreviations: U0126, MEK1/2 blocker; CHX (cycloheximide), translation
inhibitor and Actino D (actinomycin D), transcription inhibitor.
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responses, we silenced Stat3 by using small interfering RNA
(siRNA) targeting Stat3. As shown in Fig. 6, Stat3 protein
expression was decreased by 68±8% and 74±7%, 24 h and
48 h, respectively, after transfection of cardiomyocytes with
siRNA directed against Stat3, when compared to cells
transfected with non-silencing siRNA. This Stat3 knock-
down effect remained sustained until 90 h after transfection
with anti-Stat3 siRNA (Fig. 6). By contrast, Stat1 expression
was not affected in these Stat3-silenced cells, confirming the
specificity of the siRNA used.
As illustrated in Fig. 7, in cells transfected with non-
silencing siRNA, PGE2 induced a significant increase in
both, protein synthesis, as measured by [3H]-leucine
incorporation into total protein (Fig. 7A), and cell surface
(Fig. 7B). These responses were abolished when cells were
transfected with anti-Stat3 siRNA. These findings indicate
that Stat3 plays a key role in PGE2-induced cardiomyocyte
hypertrophy.
4. Discussion
The major finding of this study is that in neonatal
ventricular cardiomyocytes, PGE2 induces the activation of
Stat3 which plays an essential role in PGE2-induced increase
in protein synthesis and cell size.In the present work, we show for the first time that in
ventricular cardiomyocytes, PGE2 induces Stat3 activation
characterized by an increase in its tyrosine phosphorylation
level and its DNA-binding activity. Using various agonists
and antagonists of the G-protein-coupled PGE2 receptor
subtypes EP1–EP4, including two potent and specific
inhibitors of EP4 [23,24], we found that PGE2 activates
Stat3 mainly through the EP4 receptor although we cannot
exclude a possible involvement of EP3. Consistent with
these results, it has recently been shown that PGE2 induces
hypertrophic responses in cardiomyocytes acting through the
EP4 receptor subtype [5,6]. Moreover several studies
reported a high expression level of EP4 in heart tissue
[33–35].
Interestingly, the selective, cell-permeant, cAMP com-
petitive inhibitors of protein kinase A, Rp-cAMPS and Rp-8-
CPT-cAMPS had no effect on PGE2-induced Stat3 phos-
phorylation. Consistently, the adenylate cyclase activator
forskolin did not induce Stat3 phosphorylation. These results
are in agreement with recent investigations on EP4 signaling.
Indeed, although initial studies on EP4 indicated that
activation of this receptor increases cAMP formation [32],
it has been shown recently that PGE2 stimulation induces the
expression of early growth response factor-1 mainly through
ERK1/2 [36].
In our study we also found a role for ERK1/2 in PGE2
signaling. Indeed, we observed that in ventricular cardio-
myocytes, 100 nM PGE2 induces an important transient
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maximal values after 2–5 min. By contrast, PGE2 appears to
have no effect on p38 MAPK. These results are in agreement
with those of Mendez and LaPointe [5] who recently
reported that 1 μM PGE2 induces the phosphorylation of
ERK1/2 through the EP4 receptor. We also found that
inhibition of the serine/threonine kinase ERK1/2, but not of
the p38 MAPK pathway, abolished not only PGE2-induced
Stat3 DNA-binding but also its phosphorylation on tyrosine.
On the one hand, these results clearly demonstrate that
ERK1/2 activation is a necessary event for PGE2-induced
Stat3 activation. On the other hand, they further indicate that
Stat3 is not the direct target of ERK1/2 in our system, although
it has been shown in vitro that Stat3 is an excellent substrate for
ERKs [37] and that activation of Stat3 can be modulated by
serine phosphorylation [26,37]. The indirect role of ERK1/2 is
further supported by our finding that the translation inhibitor
cycloheximide blocks the PGE2-induced Stat3 tyrosine
phosphorylation. Our observations are consistent with that of
Ng et al. [27], showing that in cardiomyocytes, interleukin-1β-
induced Stat3 tyrosine phosphorylation is reduced following
ERK1/2 inhibition and requires protein synthesis. Taking into
account both, the fact that linking PGE2-induced ERK1/2
activation and Stat3 phosphorylation requires an intermediate
tyrosine kinase and our finding that protein synthesis is
involved in the delayed phosphorylation of Stat3, we propose
two hypothesis. First, newly synthesized protein(s) would
remain in the cell and being or inducing a non-receptor
tyrosine kinase would lead to Stat3 activation. Second, newly
synthesized protein(s) would be released and would act in an
autocrine manner to stimulate a receptor-associated tyrosine
kinase. This more indirect mechanism could involve cyto-
kines of the interleukin-6 (IL-6) family whose receptors are
expressed in cardiomyocytes [38] and are well known to
activate Stat3. Consistent with this hypothesis, angiotensin II
was shown to induce Stat3 tyrosine phosphorylation through
the autocrine action of secreted IL-6 family cytokines [13].
Moreover, we found previously that in neonatal rat ventricular
cardiomyocytes, PGE2 induces IL-6 mRNA expression [2].
Further investigations are needed to elucidate all the steps
involved in the delayed activation of Stat3 by PGE2.
An important part of our study was to investigate the role
of Stat3 in PGE2-induced cardiomyocyte hypertrophy. To this
purpose we determined protein synthesis and cell size, two
key features of cardiomyocyte hypertrophy which have been
shown to be increased following stimulation with PGE2 [5].
By electroporating neonatal ventricular cardiomyocytes with
siRNA targeting specifically rat Stat3, we obtained an
approximately 70% inhibition of Stat3 expression. In these
Stat3 silenced cardiomyocytes, the PGE2-induced increase
in protein synthesis and cell size was abolished. These
results demonstrate that Stat3 activation is essential for PGE2-
induced hypertrophic responses in ventricular cardiomyo-
cytes, a finding which is consistent with the present knowl-
edge of Stat3 playing an important role in the regulation of
cardiac hypertrophy [7–9,14,15].Taking into account all our data, we propose the model
shown in Fig. 8. In neonatal ventricular cardiomyocytes,
PGE2 activates the EP4 receptor which leads to the stim-
ulation of the MEK1/2–ERK1/2 pathway inducing the
phophorylation of Stat3. According to our experiments with
actinomycin D and cycloheximide, the PGE2-induced Stat3
phosphorylation involves newly synthesized yet-to-be-
determined protein(s). After its phosphorylation, Stat3 di-
merizes and translocates to the nucleus where it induces the
transcription of target genes leading finally to characteristic
hypertrophic responses such as an increase in protein
synthesis and cardiomyocyte size.
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